Crinetics Pharmaceuticals (CRNX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Welcome to day two of the Jefferies Healthcare Conference. My name is Dennis Dane, biotech analyst here at Jefferies. I have the great pleasure of having Kinetics Pharmaceuticals here with us and CEO, Scott Struthers, will give a brief presentation and then maybe we can do a little bit of Q and A afterwards. Speaker1 Thanks, Ness, and thanks everybody. It's a little loud so I'll stand back a bit, but I see a bunch of folks I ...

SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies Global Healthcare Conference 2025Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern TimeWebcast link: HERE The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at ...

New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL. One pres ...

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and granted an aggregate of 101,800 restricted stock unit (“RSU”) awards to 35 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 In ...

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $0.93 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.05%. A quarter ago, it was expected that this company would post a loss of $0.92 per share when it actually produced a loss of $0.88, delivering a surprise of 4.35%.Over the last four quarters, the compa ...

Crinetics Pharmaceuticals (CRNX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Gayathri Diwakar - Head of IRR. Scott Struthers - Founder & CEOIsabel Kalofonos - Chief Commercial OfficerDana Pizzuti - Chief Medical & Development OfficerTobin Schilke - CFO & Principal Accounting OfficerAlan Krasner - Chief EndocrinologistGavin Clark-Gartner - Director - Biotechnology Equity ResearchAlex Thompson - Managing DirectorWill Soghikian - Vice President - Equity ResearchDouglas Tsao - Managing D ...

Crinetics Pharmaceuticals (CRNX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Welcome to the Kinetics Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in listen only mode. Following the management's prepared remarks, we will hold a question and answer session. I would now like to turn the call over to Gayatri Tewakkar, Head of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Good afternoon, everyone, and thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3744114 (State or other j ...

Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromising Primary Endpoint to Normalize Androstenedione Levels with Physiologic Glucocorticoid Replacement Exhibit 99.1 Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update R&D Day Sche ...

Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromising Primary Endpoint to Normalize Androstenedione Levels with Physiologic Glucocorticoid Replacement R&D Day Scheduled for June 26 to Share Early-Stage Pipeline Strategy and Data $1.3B in Cash, Cash Equivalents, and Investme ...